Psychedelics ‘show some promise’ for select patients, TGA told
An independent panel has reviewed the literature on MDMA and psilocybin
The psychedelic substances psilocybin and MDMA (ecstasy) hold some potential for treating mental illness in a select group of patients, an expert panel suggests. 
However, in a report to the TGA, the group stressed their findings only applied to the drugs being administered under close clinical supervision with intensive support.
It comes as the medicines regulator considers a bid to reschedule psilocybin and MDMA from being classed as prohibited substances (S9) to controlled drugs (S8).
The TGA commissioned the report evaluating the therapeutic value, benefits and risks of the substances ahead of its final decision due in early December.
